Clinical trialsCompany release

Acumen's sabirnetug misses primary endpoint in Phase 2 Alzheimer's trial; development to stop

🇺🇸 Acumen Pharmaceuticals, Inc. (ABOS) · Fri 30 Oct 2026

Acumen Pharmaceuticals says ALTITUDE-AD failed on its primary iADRS measure at both doses, and the company will end work on the amyloid antibody and explore strategic options.

Acumen Pharmaceuticals reported on 30 October 2026 that its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease did not meet its primary endpoint. Neither dose tested separated from placebo on the integrated Alzheimer's Disease Rating Scale (iADRS).

Key secondary endpoints, including the Clinical Dementia Rating-Sum of Boxes (CDR-SB), were also missed, according to the company's announcement.

Sabirnetug did reduce amyloid plaque and was generally well tolerated. Amyloid-related imaging abnormalities with oedema (ARIA-E) occurred in about 10% of treated participants.

Acumen said it will stop developing sabirnetug, including the open-label extension study. It plans to conserve cash and explore strategic options. The material available to VigiEye did not include further detail on timelines, trial data beyond these headline points, or the strategic process.

What it means for your team

  • Sabirnetug's discontinuation removes a clinical-stage amyloid-targeting antibody from the early Alzheimer's pipeline; no regulatory filing was reported as planned.
  • Safety teams tracking the anti-amyloid class can note the reported ARIA-E rate of about 10%, though full data have not been detailed in the material available.
  • Sites and sponsors involved in the open-label extension should expect wind-down activity, as the company has said that study will end.

Company's press release (SEC filing): Acumen Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Acumen Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →